Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.55 |
| ▸ | THRA | P10827 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13802434 | 0.95 | PTGDR2 (0.53) | PTGDR2THRATHRBPLA2G2AABCB1 | |
| SCHEMBL13802436 | 0.94 | PLA2G2A (0.55) | PTGDR2THRATHRBPLA2G2AABCB1 | |
| SCHEMBL8174614 | 0.77 | ABCC4 (0.41) | PTGDR2THRATHRBABCB1PTGS1 | |
| SCHEMBL8173729 | 0.77 | PTGER4 (0.45) | ABCB1PTGER4 | |
| SCHEMBL28174704 | 0.77 | CNR2 (0.58) | PTGDR2THRATHRBEGFRALDH1A1 | |
| SCHEMBL28370067 | 0.76 | THRA (0.57) | PTGDR2THRATHRBPLA2G2AABCB1 | |
| SCHEMBL13802413 | 0.76 | ABCB1 (0.58) | PTGDR2PLA2G2AABCB1PTGS1PTGS2 | |
| SCHEMBL13802422 | 0.76 | PTGDR2 (0.76) | PTGDR2THRATHRBPLA2G2APTGS2 | |
| SCHEMBL13802423 | 0.76 | PTGDR2 (0.61) | PTGDR2THRATHRBPLA2G2AABCB1 | |
| SCHEMBL18698713 | 0.75 | CNR2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | PTGDR2 2287/4885THRA 3787/4885THRB 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.